Loading company…
ResistanceBio identifies cancer resistance targets and develops potential therapeutics.
ResistanceBio is a California-based biotechnology company founded by Nick Goldner and Chris Bulow. Its ResCu platform analyzes cancer cell resistance to clinical treatments and identifies resistance targets and biomarkers to support the development of cancer therapies. The company is part of the Alumni Ventures portfolio.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in